Erasca (ERAS) Times Interest Earned (2020 - 2025)
Erasca (ERAS) reported Times Interest Earned of -$470.68 for Q2 2025, down 219.42% on a YoY basis from $394.12 in Q2 2024, and little changed quarter-over-quarter from -$468.82 in Q1 2025.
Erasca (ERAS) Times Interest Earned (2020 - 2025) Analysis & Trends
Erasca has reported Times Interest Earned for 6 years, with the latest figure at -$470.68 in Q2 2025.
- For the quarter ending Q2 2025, Times Interest Earned fell 219.42% year-over-year to -$470.68; the trailing twelve-month figure through Mar 2026 stood at -$3619.6 (down 1000.04% YoY), and the FY2025 full-year result was -$568.17, down 582.1% from the prior year.
- Times Interest Earned for Q2 2025 stood at -$470.68, roughly flat from -$468.82 in the prior quarter.
- The five-year high for Times Interest Earned was -$147.35 in Q2 2024, with the low at -$2761.6 in Q4 2022.
- Historically, Times Interest Earned has averaged -$672.7 across 5 years, with a median of -$544.85 in 2022.
- Annual changes were most pronounced in 2023 — Times Interest Earned surged 81.69% — and 2025, when it sank 219.42%.
- Erasca's Times Interest Earned stood at -$622.22 in 2021, then slumped by 343.83% to -$2761.6 in 2022, then surged by 81.69% to -$505.55 in 2023, then surged by 70.85% to -$147.35 in 2024, then slumped by 219.42% to -$470.68 in 2025.
- The last three Times Interest Earned figures came in at -$470.68 (Q2 2025), -$468.82 (Q1 2025), and -$147.35 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -470.68 |
| Mar 31, 2025 | -468.82 |
| Jun 30, 2024 | -147.35 |
| Mar 31, 2024 | -588.65 |
| Dec 31, 2023 | -505.55 |
| Sep 30, 2023 | -707.31 |
| Jun 30, 2023 | -580.16 |
| Mar 31, 2023 | -725.98 |
| Dec 31, 2022 | -2,761.56 |
| Sep 30, 2022 | -754.33 |
| Jun 30, 2022 | -394.56 |
| Mar 31, 2022 | -544.85 |
| Sep 30, 2021 | -622.22 |
| Jun 30, 2021 | -462.03 |
| Mar 31, 2021 | -356.49 |
| Sep 30, 2020 | -293.76 |
| Jun 30, 2020 | -220.73 |